The request from Senators indicates a regulatory interest in Eli Lilly's insulin affordability programs. While this could potentially lead to changes in the company's practices, the company's positive response suggests they are prepared to cooperate and address any concerns. This is likely to have a neutral impact on the stock in the short term.